Connect with us

Small Caps

EXCLUSIVE: Arianne Phosphate’s Brian Ostroff On The Crisis Facing The Global Food Supply

Few people come to the dining room table without realizing the importance of phosphate in the creation of their meal.
Phosphate is a form of the mineral…

Published

on

Few people come to the dining room table without realizing the importance of phosphate in the creation of their meal.

Phosphate is a form of the mineral nutrient phosphorous that crops absorb through fertilizer. Prior to the coronavirus pandemic, many agricultural chemists were warning that the global peak in phosphorus production could occur around 2030. But the post-pandemic chaos with historic inflation, supply chain disruptions and a war between Russia and Ukraine has brought hitherto unexpected difficulties to this equation.

To understand the challenges facing the global availability of phosphate, Benzinga spoke with Brian Ostroff, CEO at Arianne Phosphate, Inc. (OTC: DRRSF), a Canadian mining company primarily focused on developing Lac à Paul phosphate rock project located in the Saguenay-Lac St-Jean area, Quebec.

Brian Ostroff

For the benefit of those who are not up to speed on the subject, what is the value of phosphate?

Phosphate is one of the three macronutrients in fertilizer – nitrogen and potash being the other two. A lot of people make the mistake and say, ‘Oh, it's all fertilizer’ – and that's really not accurate because you need all three, depending on the grain that you're growing. Some are more intensive, like corns, while soybeans are less intensive.

If, for whatever reason, you can't get phosphate, you can't put on twice as much potash or anything like that. And not all phosphates are the same. With gold, for example, if you pull it out of the ground in Quebec or Nevada or Siberia, your end products are all the same. Phosphate will vary from mine to mine.

Most of the world's phosphate comes from sedimentary deposits. I won't bore you with geology, but the challenge with sedimentary deposits is they tend to have a lot of deleterious elements in them – namely, radioactive elements and heavy metals. And, of course, since you're ultimately talking about food, that's not a wonderful thing. So, you try and deal with it, because the reality is without mined phosphate, studies have shown that 80% of the world's population is going to starve to death.

See ...

Full story available on Benzinga.com

Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Science

Hot Penny Stocks to Buy This Week? 3 For Your List 

Can these penny stocks continue to climb
The post Hot Penny Stocks to Buy This Week? 3 For Your List  appeared first on Penny Stocks to Buy, Picks, News…

Published

on

3 Hot Penny Stocks to Add to Your Watchlist This Week 

Let’s face it, finding penny stocks to buy is not easy. And over the past few months, it has been increasingly challenging to make money with small caps. Now, while this may be true, not every investor has lost money in that time. Rather, to make money with penny stocks, traders have to be extra careful and know what penny stocks to buy. 

[Read More] Best Penny Stocks to Buy as June Ends? 3 to Watch 

There are a few key things to look for when finding penny stocks to buy. The first is a reason that it may move. When penny stocks shift up or down, there are numerous causes. But, most penny stocks will have a fundamental reason to do so. This could be a new product launch, an FDA approval, or anything else that would increase demand for the company’s shares. 

The second is liquidity. This is key because you need to be able to buy and sell penny stocks quickly. If there is not enough liquidity or shares traded in a day, you may be stuck with your penny stock. 

The last is price. You obviously want to buy penny stocks that are cheap, but you also want to make sure that the company is valued appropriately. This means looking at its fundamentals and understanding why it is at its given value. With all of this in mind, let’s take a look at three penny stocks to add to your watchlist this week.

3 Penny Stocks to Watch This Week 

  1. Visionary Education Technology Holding Group Inc. (NASDAQ: VEDU)
  2. RLX Technology Inc. (NYSE: RLX)
  3. Uranium Energy Corp. (NYSE: UEC

Visionary Education Technology Holding Group Inc. (NASDAQ: VEDU) 

One of the largest gainers of the day on June 27th was VEDU stock. By EOD, shares of VEDU had shot up by more than 30% with an over 5% after-hours gain. And, in the past five days, shares of VEDU stock have exploded by over 120%. These major gains come alongside no recent news. The most recent news however, came on May 19th. 

[Read More] Penny Stocks: Looking At The Big Picture For Tiny Stocks

On the 19th, the company announced the closing of its $17 million firm commitment IPO. This came with 4.25 million shares at a public offering price of $4 per share. For some context, Visionary Education is a Canadian based company offering high-quality education resources to students around the world. While it has fallen from its IPO price to around $2.60, its recent bullish momentum is exciting without a doubt. So, with all of this in mind, will VEDU be on your penny stocks watchlist or not?

RLX Technology Inc. (NYSE: RLX) 

With over 3% in gains during trading and after hours on June 27th, RLX is another penny stock that investors are watching right now. In the past month, we’ve seen shares of RLX climb by more than 19%, which is no small feat. The most recent news from the company came in the form of its unaudited Q1 2022 financial results. In the results, the company saw its net revenue decline slightly, however, it stated that this was due to the pandemic. 

“During the first quarter of 2022, we continued to focus on our core strategy and maintain our leading position in the industry while preparing for the anticipated regulatory changes.

As the new regulatory framework has come into effect and detailed implementation measures have been released, we are proactively adapting our business to the new market environment by applying for the relevant licenses and developing qualified products that meet the requirements of the most recent national standards.”

The CEO of RLX Technology, Ms. Ying Wang

While this news was not ideal, it did bring shares of RLX stock down to lower levels. And as a result, its recent bullish momentum could be due to RLX being at value prices. Whether this makes RLX worth adding to your list of penny stocks to buy, is up to you. 

Penny_Stocks_to_Watch_RLX

Uranium Energy Corp. (NYSE: UEC) 

On June 27th, UEC stock saw modest gains however, it did post abnormally high volume. And because of this, many investors are keeping a close eye on it right now. The most recent update from the company came on June 22nd, when it announced its entrance into a definitive agreement with UEX Corporation. It stated that it would acquire all of the outstanding shares of UEX with a C$5 million private placement. 

This is big news for the company and should add to its large and growing business. If you’re not familiar, Uranium Energy is a uranium mining company. And, recently, we’ve seen heightened interest in alternative energy penny stocks. And although UEC is highly volatile, it is an interesting penny stock to watch. With this considered, does UEC deserve an addition to your watchlist or not?

Penny_Stocks_to_Watch_Uranium

Which Penny Stocks Are You Buying Right Now?

After a relatively flat day of trading, investors are looking for the best penny stocks to buy this week. That involves understanding what factors are impacting the stock market, and how we can use those to benefit.

[Read More] Penny Stocks To Watch: Why EVFM, AGRX, CYBN, HILS & AFIB Stock Are Moving

Although trading is not easy, there are plenty of ways to find penny stocks to buy in 2022. So, with this in mind, which penny stocks are you buying right now?

[reblex id='29520']

The post Hot Penny Stocks to Buy This Week? 3 For Your List  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Read More

Continue Reading

Economics

Best Penny Stocks to Buy as June Ends? 3 to Watch 

Check these three penny stocks out right now
The post Best Penny Stocks to Buy as June Ends? 3 to Watch  appeared first on Penny Stocks to Buy, Picks,…

Published

on

3 Penny Stocks to Watch as June Comes to an End 

With a relatively flat day of trading for penny stocks and blue chips, there is a lot that investors need to know. Right now, we have many factors that are impacting the trajectory of penny stocks. After the last few months of incredibly bearish trading, the last week has shown a major bullish turn around. 

[Read More] Penny Stocks: Looking At The Big Picture For Tiny Stocks

Despite this, Monday, June 27th did not see a strong trading day. Rather, the day ended mostly flat for stocks across the board. The major news in the market remains rising inflation and climbing interest rates. All of this has bolstered volatility and created an incredibly topsy turvy stock market. So, while there is a lot of optimism in the stock market right now, it is incredibly cautious. 

As a result of this, traders are showing extreme care when picking penny stocks to buy. And while it can seem simple considering what is going on in the world, there are plenty of nuances that penny stocks investors need to consider. So, with all of this in mind, let’s take a look at three penny stocks to add to your end of June watchlist. 

3 Penny Stocks For Your End of June Watchlist 

  1. Neurosense Therapeutics Ltd. (NASDAQ: NRSN)
  2. Toughbuilt Industries Inc. (NASDAQ: TBLT
  3. Zomedica Corp. (NYSE: ZOM

Neurosense Therapeutics Ltd. (NASDAQ: NRSN) 

One of the largest gainers of the day on June 27th is NRSN stock which shot up by over 57%. And in the past five days, we’ve seen shares of NRSN stock climb by over 60%. The main news from the company came today when it announced positive results from Stage III ALS Biomarker Study. In the study, the company stated that preliminary results showed a statistically significant decline in biomarkers treated with its PrimeC compound. And, this validates its clinical strategy moving forward. 

“These results are very encouraging, especially in that they validate NeuroSense’s clinical strategy. The biomarker study, along with the data we collect from our Phase IIb study, will inform the optimization of a pivotal Phase III study of PrimeC in ALS. NeuroSense is honored to collaborate with the world-class MGH team on this critical study.”

The CEO of Neurosense, Alon Ben-Noon

This is a big breakthrough for the company and one that comes after months of work. So, with this in mind, does NRSN deserve a spot on your penny stocks watchlist?

Toughbuilt Industries Inc. (NASDAQ: TBLT) 

TBLT is a penny stock that we have discussed numerous times recently. And on June 27th, the company saw shares climb by over 13% at EOD. This major gain comes alongside a five day explosive trading pattern that saw TBLT climb more than 100%. And despite a six month drop of over 95%, shares of TBLT are continuing to see bullish momentum right now. The biggest recent news comes as the company announced the closing of a $6 million public offering of common stock.

[Read More] Penny Stocks To Watch: Why EVFM, AGRX, CYBN, HILS & AFIB Stock Are Moving

It states that these funds will be used for general corporate purposes, working capital, and repurchasing exciting warrants. If you’re not familiar, Toughbuilt is a provider of innovative tools. This includes those under its brand name, where it has been selling for almost a decade. With so much attention being paid to Toughbuilt, it makes sense that it would see these major bullish climbs. Whether this makes it worth adding to your list of penny stocks to buy, is up to you. 

Penny_Stocks_to_Watch_Toughbuilt

Zomedica Corp. (NYSE: ZOM) 

With a five day uptick of more than 3% and over 10% in the past month, ZOM is another penny stock that investors are watching. Recently, we’ve seen shares of Zomedica stock show extremely high volume compared to its average. And as a result of this, it is definitely worth talking about. The most recent news from the company came when it presented in a panel discussion at the Animal Health Investment Forum.

Prior to this, the company stated that it would acquire the assets of the veterinary imaging company, Revo Squared. Revo is a producer of the MicroView digital cytology platform, which offers high-quality veterinary imaging. Because of that, the company has continued to see attention in the past few weeks. 

“They have done a great job of developing the MicroView system to this point, and we look forward to them leading the effort to integrate the MicroView system into the MyZomedica customer interface, commence manufacturing at our Zomedica manufacturing center in Alpharetta and bring it to market.”

The CEO of Zomedica, Larry Heaton

Throughout the course of the pandemic, the amount of animals adopted has increased dramatically. Because of this, there has been an incredible focus on veterinary-related companies. So, while it is tough to say what the long term trajectory of Zomedica is, it could be worth keeping an eye on right now. 

Penny_Stocks_to_Watch_Zomedica

Which Penny Stocks Are You Watching Right Now?

If you’re looking for the best penny stocks to buy, there are hundreds of options to choose from. As a result of this, investors need to understand exactly what is going on in the stock market and how to take advantage.

[Read More] What to Know About Buying Penny Stocks on June 27th

This means having a well thought out trading strategy and understanding how to utilize that. Although trading in 2022 can be complicated, with the right market insights, it can be much easier than previously imagined. With this in mind, which penny stocks are you watching right now?

[reblex id='29520']

The post Best Penny Stocks to Buy as June Ends? 3 to Watch  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Read More

Continue Reading

Spread & Containment

Innovation Pharmaceuticals Inc (OTCMKTS: IPIX) Breaking Out as Biotech Reports Brilacidin Inhibits Omicron, Delta, Gamma and Alpha SARS-CoV-2 Variants Based on In Vitro Testing

Innovation Pharmaceuticals Inc (OTCMKTS: IPIX) is moving steadily northbound with power after the Company reported Brilacidin, its defensin-mimetic drug…

Published

on

Innovation Pharmaceuticals Inc (OTCMKTS: IPIX) is moving steadily northbound with power after the Company reported Brilacidin, its defensin-mimetic drug candidate exhibiting broad-spectrum antiviral activity, inhibited the Omicron and Delta variants of SARS-CoV-2 based on in vitro testing conducted in collaboration with (NIH) and (NIAID) scientists. Researchers at Rutgers University have also shown Brilacidin inhibited in vitro the Gamma and Alpha variants of SARS-CoV-2. Brilacidin has now been tested in vitro in seven SARS-CoV-2 strains (Omicron, Delta, Gamma, Alpha, Italian, Washington, Wuhan) and three human coronavirus (H-CoV) strains (OC43, 229E, and NL63), in addition to MERS-CoV and SARS-CoV-1. Brilacidin has consistently inhibited all coronaviruses tested, independent of cell type, at generally attainable systemic concentrations (based on established human pharmacokinetics of IV-administered Brilacidin).  

Emerging SARS-CoV-2 variants, and increasingly their sub-variants, contain immunity-evading mutations. These mutations alter key parts of the SARS-CoV-2 spike protein that attach to human cells, making the virus more transmissible and potentially more virulent. Unlike other antivirals, such as monoclonal antibodies, and most vaccines, Brilacidin has been shown not to target the Spike S1 and Spike RBD regions of SARS-CoV-2, acting instead through dual-acting neutralizing and blocking antiviral properties, able to target virus and host. These antiviral traits support Brilacidin’s ability to maintain its anti-coronavirus activity and suggest Brilacidin would be less subject to resistance. Taken together, the results from NIH/NIAID testing of Brilacidin are supportive of previously completed research and give the Company confidence in the compound’s antiviral potential. The Company remains active in pursuing additional government-based funding opportunities, as well as licensing partnerships, to advance Brilacidin in the highly attractive area of developing novel broad-spectrum medicines for treating viral diseases. Microcapdaily has been reporting on IPIX for a long time and we were there when the stock (then trading as CTIX) made a legendary run skyrocketing to $4.93 per share. 

Subscribe To Our 100% Free Penny Stock Newsletter!

Innovation Pharmaceuticals Inc (OTCMKTS: IPIX) is a clinical stage pharmaceutical company developing innovative therapies with anti-infective, oncology, anti-inflammatory and dermatology applications. The Company owns the rights to Brilacidin, its lead drug in a new class of compounds called defensin-mimetics, and Kevetrin (thioureidobutyronitrile), its anti-cancer compound. Brilacidin is being studied by the Company, as well as other independent researchers, as a potential broad-spectrum antiviral therapeutic for the treatment of viruses including the novel coronavirus (SARS-CoV-2), which is responsible for COVID-19. 

Brilacidin is Innovation Pharma’s lead drug candidate in its Host Defense Protein (HDP)-mimetic franchise. Brilacidin has been granted Fast Track designation by the FDA and currently is being evaluated in a randomized, placebo-controlled Phase 2 clinical trial in hospitalized COVID-19 patients (see NCT04784897). Two independent Machine Learning (AI) studies also identified Brilacidin as one of the most promising inhibitors of SARS-CoV-2, the virus responsible for COVID-19, based on Brilacidin’s molecular properties. Modeled after HDPs, the “front-line” of defense in the body’s innate immune system, it is a synthetic, non-peptidic small molecule that kills pathogens swiftly, significantly reducing the likelihood of drug resistance developing. Just as importantly, Brilacidin functions in a robust immunomodulatory capacity, lessening inflammation and promoting healing. 

Kevetrin is a small molecule that has demonstrated the potential of becoming a breakthrough cancer treatment by inducing activation of p53, a protein frequently referred to as the “Guardian of the Genome” due to its critical role in controlling cell mutations. In most cancers, regardless of origin, type, and location, the p53 pathway becomes inactivated (dysfunctional), thus preventing the body from performing its natural anti-tumor functions. The TP53 gene is the most studied gene of all time. Conducted at the Dana-Farber Cancer Institute and at Beth Israel Deaconess Medical Center, a Phase 1 clinical trial evaluating Kevetrin in treating Advanced Solid Tumors has been successfully completed, with patients showing good toleration and encouraging signs of potential therapeutic response. The Company has concluded its open-label, dose-escalation Phase 2a trial of Kevetrin in Platinum-Resistant/Refractory Ovarian Cancer. Highly encouraging preliminary data from the first patients treated in the trial showed modulation of the p53 protein in response to administration of Kevetrin. With a promising bioavailability profile, and to leverage its short half-life (the drug exits the body in approximately 8 to 10 hours), efforts are underway to develop Kevetrin as an oral anti-cancer agent (tablet or capsule) that can be administered daily, potentially even multiple times per day. The FDA has awarded Kevetrin Orphan Drug status for Ovarian Cancer, Pancreatic Cancer, and Retinoblastoma, qualifying it for developmental incentives and an extra 7 years of market exclusivity upon drug approval. The FDA also has granted Kevetrin Rare Pediatric Disease designation for childhood Retinoblastoma. 

Microcapdaily has been covering IPIX for years starting with CTIX back in 2015 reporting on the stocks legendary run to $4.93 per share. We stated on CTIX back in the day: “As anyone in the industry knows, regulating the p53 pathway has long been the holy grail of cancer research and big pharma has spent hundreds of millions of dollars researching ways to achieve this with no success thus far. It seems Kevetrin(TM) has accomplished this; extensive preclinical research on Kevetrin shows the re-activation of p53 across a wide spectrum of cancer lines including colon, lung, breast and pancreatic cancers. The market potential for Kevetrin in treating drug-resistant cancers is worth $5 billion a year. Other cancers could easily represent an additional $5 billion annually, he adds.”

IPIX has established a valuable intellectual property portfolio: 

To Find out the inside Scoop on IPIX Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

IPIX

On June 23 IPIX reported Brilacidin, the Company’s defensin-mimetic drug candidate exhibiting broad-spectrum antiviral activity, inhibited the Omicron (B.1.1.529) and Delta (B.1.617.2) variants of SARS-CoV-2 based on in vitro testing conducted in collaboration with National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) scientists. Researchers at Rutgers University have also shown Brilacidin inhibited in vitro the Gamma (P.1) and Alpha (B.1.1.7) variants of SARS-CoV-2. Brilacidin has now been tested in vitro in seven SARS-CoV-2 strains (Omicron, Delta, Gamma, Alpha, Italian, Washington, Wuhan) and three human coronavirus (H-CoV) strains (OC43, 229E, and NL63), in addition to MERS-CoV and SARS-CoV-1. Brilacidin has consistently inhibited all coronaviruses tested, independent of cell type, at generally attainable systemic concentrations (based on established human pharmacokinetics of IV-administered Brilacidin). Identifying COVID-19 countermeasures with novel mechanisms of action is vital. SARS-CoV-2 continues to evolve at an accelerated pace, raising questions as to what the dominant variant (or sub-variant) may be this fall and winter, when infections often spike — and if today’s COVID-19 vaccines and therapeutics can maintain their effectiveness. 

Emerging SARS-CoV-2 variants, and increasingly their sub-variants, contain immunity-evading mutations. These mutations alter key parts of the SARS-CoV-2 spike protein that attach to human cells, making the virus more transmissible and potentially more virulent. Unlike other antivirals, such as monoclonal antibodies, and most vaccines, Brilacidin has been shown not to target the Spike S1 and Spike RBD regions of SARS-CoV-2, acting instead through dual-acting neutralizing and blocking antiviral properties, able to target virus and host. These antiviral traits support Brilacidin’s ability to maintain its anti-coronavirus activity and suggest Brilacidin would be less subject to resistance. Related, results from new NIH/NIAID in vitro testing of Brilacidin in over 20 acutely infectious viruses, and from the Brilacidin Phase 2 COVID-19 clinical trial, are being prepared for publication. Findings from the Rutgers’ Brilacidin research can be accessed at the link below1 and build on earlier published Brilacidin research conducted by scientists at George Mason University and at University of Arizona and University of California-San Francisco. 

In 2021, the Company completed a Phase 2 clinical trial of Brilacidin (NCT04784897) for treatment of moderate-to-severe COVID-19 patients. While the trial did not meet its primary endpoint in reducing time to sustained recovery through day 29, certain patient subgroups did show treatment benefits of Brilacidin for that primary endpoint. For example, patients treated early from onset of symptoms achieved sustained recovery more quickly (Brilacidin 5-dose group vs pooled placebo, p=0.03). To date, only a modicum of success has been demonstrated by any company conducting clinical trials in moderate-to-severe hospitalized cases of COVID-19. A possible reason for this may be owing to frequent changes in the standard of care with patients receiving a cocktail of fluctuating concomitant medications, which complicates the interpretation of the clinical trial data and that of the new drug candidate being evaluated. Clinical observations of COVID-19 patients treated with Brilacidin further lead us to believe that higher and more frequent dosing of Brilacidin may be more appropriate to tackle this complex disease in the hospital setting. 

Taken together, the results from NIH/NIAID testing of Brilacidin are supportive of previously completed research and give the Company confidence in the compound’s antiviral potential. The Company remains active in pursuing additional government-based funding opportunities, as well as licensing partnerships, to advance Brilacidin in the highly attractive area of developing novel broad-spectrum medicines for treating viral diseases. 

For More on IPIX Subscribe Right Now!

Currently trading at an $18 million market valuation IPIX has $8.7 million in the treasury, over $11 million in assets vs. $4.5 million in total liabilities. IPIX is CTIX reincarnated and this stock can move skyrocketing to $4.93 per share back in the day; a run we reported on from the beginning. IPIX is heating up and getting noticed by investors after the Company reported Brilacidin, its defensin-mimetic drug candidate exhibiting broad-spectrum antiviral activity, inhibited the Omicron and Delta variants of SARS-CoV-2 based on in vitro testing conducted in collaboration with (NIH) and (NIAID) scientists. Researchers at Rutgers University have also shown Brilacidin inhibited in vitro the Gamma and Alpha variants of SARS-CoV-2. Brilacidin has now been tested in vitro in seven SARS-CoV-2 strains (Omicron, Delta, Gamma, Alpha, Italian, Washington, Wuhan) and three human coronavirus (H-CoV) strains (OC43, 229E, and NL63), in addition to MERS-CoV and SARS-CoV-1. Brilacidin has consistently inhibited all coronaviruses tested, independent of cell type, at generally attainable systemic concentrations (based on established human pharmacokinetics of IV-administered Brilacidin). We will be updating on IPIX when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with IPIX.

WAIT! Do You Want Stocks That Could Go Up 348% In Days Delivered To Your Inbox For FREE?

Disclosure: we hold no position in IPIX either long or short and we have not been compensated for this article.

The post Innovation Pharmaceuticals Inc (OTCMKTS: IPIX) Breaking Out as Biotech Reports Brilacidin Inhibits Omicron, Delta, Gamma and Alpha SARS-CoV-2 Variants Based on In Vitro Testing first appeared on Micro Cap Daily.

Read More

Continue Reading

Trending